What is TRVI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.93B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TRVI?

P/E (TTM) is n/a and 52-week range is $9.82 to $20.22 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TRVI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TRVI?

The company profile lists net income (TTM) near -$49M, EPS (TTM) near -$0.34 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Trevi Therapeutics, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in New Haven, Connecticut, US, 142.5M shares outstanding, ISIN US89532M1018 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Trevi Therapeutics, Inc.

$TRVI

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. The company is headquartered in New Haven, Connecticut and currently employs 34 full-time employees. The company went IPO on 2019-05-07. The firm is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. The company has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

Employees

Website

www.trevitherapeutics.com/

IPO

2019-05-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US89532M1018

Headquarters

New Haven, Connecticut, US

Shares outstanding

142.5M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

99.98%

Browse other companiesFree AI scores and summaries for more stocks